EUVIMEDEUVIMED entdecken
Crossref

Dermatology medications with the highest cost burden on Medicare Part D: Potential implications of the Inflation Reduction Act

Annie I Chen, Joe K Tung, Laura K Ferris

Journal of the American Academy of Dermatology · 2024

DOI: 10.1016/j.jaad.2024.04.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2024. Verfasst von Annie I Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Medicare Part D, Drug Costs, Dermatologic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Signed into law in August 2022, the Inflation Reduction Act includes provisions requiring the federal government to negotiate prices for medications covered under Medicare Part D. Initial negotiations will target drugs with the highest total spending and price increases relative to inflation. In this study, we identify dermatology prescriptions with the highest cost burden on Medicare Part D and analyze recent trends in total spending and unit costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medicare Part DDrug CostsDermatologic AgentsUnited StatesHumansInflation, EconomicDermatologyHealth Expenditures

Stichwörter der Autor:innen

Inflation Reduction ActMedicarebiologicsdrug pricesgeneral dermatologygenericsmedical dermatologypharmaceutical

Substanzen

Dermatologic Agents

Autor:innen und Institutionen

  • University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: ferrislk@upmc.edu.

Zitieren

APA

Chen, A. I., Tung, J. K., & Ferris, L. K. (2024). Dermatology medications with the highest cost burden on Medicare Part D: Potential implications of the Inflation Reduction Act. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.04.030

Vancouver

Chen AI, Tung JK, Ferris LK. Dermatology medications with the highest cost burden on Medicare Part D: Potential implications of the Inflation Reduction Act. Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2024.04.030

BibTeX
@article{Chen2024,
  author = {Chen, Annie I and Tung, Joe K and Ferris, Laura K},
  title = {Dermatology medications with the highest cost burden on Medicare Part D: Potential implications of the Inflation Reduction Act},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  doi = {10.1016/j.jaad.2024.04.030}
}
Kostenlos starten →